NHANES-based assessment of neutrophil-percentage-to-albumin and neutrophil-to-lymphocyte ratios as moderate predictors of mortality in adults with chronic respiratory diseases

基于NHANES数据的评估显示,中性粒细胞百分比与白蛋白比值和中性粒细胞与淋巴细胞比值可作为慢性呼吸系统疾病成人死亡率的中等预测指标。

阅读:1

Abstract

OBJECTIVE: This study aimed to evaluate the predictive roles of hematologic inflammatory biomarkers, including the neutrophil-percentage-to-albumin ratio (NPAR), neutrophil-to-lymphocyte ratio (NLR), and eosinophil-to-lymphocyte ratio (ELR), in relation to mortality among individuals with chronic respiratory diseases (CRDs). METHODS: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) to assess the relationship between these inflammatory biomarkers and mortality in adults with CRDs. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for all-cause mortality, adjusting for potential confounders. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the predictive performance of these biomarkers, with the area under the curve (AUC) used to compare their accuracy. RESULTS: A total of 8,387 participants with CRDs were included in the analysis. Higher levels of NPAR were significantly associated with increased all-cause mortality (HR = 1.33, 95% CI: 1.26-1.40, P < 0.001). Similarly, elevated NLR was associated with higher mortality risk (HR = 1.24, 95% CI: 1.17-1.30, P < 0.001). In contrast, ELR did not show a significant association with mortality (HR = 1.04, 95% CI: 0.99-1.10, P = 0.098). ROC curve analysis revealed that NPAR had the highest AUC value (0.639, 95% CI: 0.623-0.656), suggesting modest yet relatively better discriminative capacity among the evaluated biomarkers for mortality risk stratification. CONCLUSION: Among individuals with chronic respiratory diseases, higher NPAR and NLR are significant predictors of mortality, with statistically significant but moderate predictive ability as indicated by their AUC values. These findings suggest that NPAR and NLR may serve as useful biomarkers for risk stratification in patients with CRDs, though their clinical utility is limited by modest predictive power.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。